An observational study in Allergic Rhinitis Due to Grass Pollens, sponsored by Stallergenes Greer. Terminated at 1 site in France. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2016-04-18.
Sponsored by Stallergenes Greer · Observational
The purpose of the present study is to describe patient's perception of quality of life and effectiveness of ORALAIR® over a follow-up period up to 5 years, in real-life settings.
Primary objective:
To describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass pollen season in real-life settings.
Secondary objectives:
1,105 studies on the registry are indexed under Rhinitis; 65 are open to participants now.
This study's enrollment of 740 is above the median of 141 across 172 observational studies indexed under Rhinitis.
Browse Rhinitis studies →Stallergenes Greer is the lead sponsor of 25 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with allergic rhino-conjunctivitis are visiting their allergist during grass-pollen season when symptoms are strong. In accordance with the terms of the Marketing Authorization, ORALAIR® treatment has to be set-up "at the right moment" about 4 months before the next grass-pollen season.
Exclusion Criteria:
Patient with proven allergic rhino-conjunctivitis due to grass pollen
Health related quality of life
The primary objective is to describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass-pollen season in real-life settings.
Time frame: patients will be followed for the duration of the treatment, an expected average of 6 months/year
Treatment Effectiveness
To describe the patient's perceived effectiveness of ORALAIR® in allergic rhino-conjunctivitis management in terms of disease intensity, satisfaction and rescue medication
Time frame: patients will be followed for the duration of the treatment, an expected average of 6 months/year
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stallergenes Greer